Misonix, Inc. (NASDAQ:MSON) saw a large increase in short interest in June. As of June 30th, there was short interest totalling 265,700 shares, an increase of 33.9% from the May 30th total of 198,500 shares. Based on an average trading volume of 62,300 shares, the days-to-cover ratio is currently 4.3 days. Approximately 3.4% of the shares of the company are short sold.
NASDAQ:MSON traded down $2.04 during midday trading on Friday, reaching $23.81. 125,049 shares of the company traded hands, compared to its average volume of 94,604. Misonix has a twelve month low of $12.91 and a twelve month high of $27.54. The firm has a fifty day moving average of $24.32.
Misonix (NASDAQ:MSON) last released its quarterly earnings data on Wednesday, May 8th. The medical equipment provider reported ($0.17) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.01. Misonix had a negative return on equity of 29.13% and a negative net margin of 18.10%. The business had revenue of $9.56 million during the quarter.
Large investors have recently added to or reduced their stakes in the stock. Rathbone Brothers plc boosted its position in Misonix by 6.2% during the 1st quarter. Rathbone Brothers plc now owns 15,500 shares of the medical equipment provider’s stock valued at $298,000 after purchasing an additional 900 shares during the period. Acadian Asset Management LLC boosted its position in Misonix by 95.3% during the 1st quarter. Acadian Asset Management LLC now owns 18,558 shares of the medical equipment provider’s stock worth $357,000 after acquiring an additional 9,054 shares during the period. Geode Capital Management LLC boosted its position in Misonix by 5.3% during the 4th quarter. Geode Capital Management LLC now owns 35,095 shares of the medical equipment provider’s stock worth $561,000 after acquiring an additional 1,775 shares during the period. Finally, Tibra Equities Europe Ltd acquired a new position in Misonix during the 1st quarter worth $327,000. Institutional investors and hedge funds own 21.17% of the company’s stock.
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
Read More: Is a Roth IRA right for you?
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.